Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis with without previous Systemic Therapy for Improvement of Nail Symptoms: NAPSI Results PRIME Study

Thaci D, Reich K, Mrowietz U, Augustin M, Kneidl J, Hentschke C, Simang M, Sieder C, Melzer N, Sticherling M (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Journal der Deutschen Dermatologischen Gesellschaft Wiley-Blackwell

Book Volume: 15

Pages Range: 144-144

Authors with CRIS profile

Michael Sticherling Professur für Dermatologie

Involved external institutions

Novartis AG CH Switzerland (CH) Dermatologikum Hamburg DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE)

How to cite

APA:

Thaci, D., Reich, K., Mrowietz, U., Augustin, M., Kneidl, J., Hentschke, C.,... Sticherling, M. (2017). Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis with without previous Systemic Therapy for Improvement of Nail Symptoms: NAPSI Results PRIME Study. (pp. 144-144).

MLA:

Thaci, D., et al. "Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis with without previous Systemic Therapy for Improvement of Nail Symptoms: NAPSI Results PRIME Study." 2017. 144-144.

BibTeX: Download